Table 5 Classification of 48 validation set patients into risk groups based on the commercial and RUO ROR scores.

From: Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Commercial Prosigna ROR

RUO ROR (NanoString-derived)

Total

Low

Intermediate

High

Low

8

1

0

9

Intermediate

1

12

1

14

High

0

0

25

25

Total

9

13

26

48

Back to article page